Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
116,964,738
-
Total 13F shares
-
57,021,480
-
Share change
-
+2,279,348
-
Total reported value
-
$940,856,419
-
Put/Call ratio
-
122%
-
Price per share
-
$16.50
-
Number of holders
-
104
-
Value change
-
+$38,878,477
-
Number of buys
-
56
-
Number of sells
-
49
Institutional Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q3 2018
As of 30 Sep 2018,
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) was held by
104 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
57,021,480 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, Temasek Holdings (Private) Ltd, BlackRock Inc., Kohlberg Kravis Roberts & Co. L.P., Sofinnova Ventures Inc, Vanguard Group Inc, JPMORGAN CHASE & CO, STATE STREET CORP, Hound Partners, LLC, and CITADEL ADVISORS LLC.
This page lists
104
institutional shareholders reporting positions in this security
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.